Bio­haven’s tro­r­ilu­zole re­ject­ed be­fore FDA re­view

Bio­haven said Thurs­day it re­ceived a re­fusal-to-file let­ter from the FDA over its NDA for tro­r­ilu­zole in an an­nounce­ment that sent its share price down more than 26% in mar­ket trad­ing.

The reg­u­la­tor re­port­ed­ly told the com­pa­ny it would not re­view the drug be­cause the pri­ma­ry end­point in the study it sub­mit­ted was not met. Bio­haven said in May 2022 that tro­r­ilu­zole missed the pri­ma­ry end­point in a Phase III last year that en­rolled 213 pa­tients with dif­fer­ent types of spin­ocere­bel­lar atax­ia (SCA).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER